Quantcast

Latest lung cancer Stories

2014-03-05 10:44:37

By eliminating Mcl-1, radiation and chemotherapies could be more effective in treating the most common and deadly of all cancers Researchers at the Translational Genomics Research Institute (TGen) have discovered a protein, Mcl-1, that helps enable one of the most common and deadly types of cancer to survive radiation and drug treatments. Non-small cell lung cancer (NSCLC) makes up about 85 percent of the nearly 160,000 Americans expected to die this year from lung cancer, which by far...

2014-03-04 23:30:56

The Sensus Healthcare SRT-100™ is a non-invasive skin cancer treatment system. The SRT-100™ will provide the local patient community with the most effective, non-surgical and pain free therapy to treat non-melanoma skin cancers, such as Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC), which account for the vast majority of all skin cancers. Roslyn Heights, NY (PRWEB) March 04, 2014 Skin Cancer Radiotherapy Institute (SCRI) announced that they are the first medical...

2014-03-04 12:26:37

Doug Kammerer Chosen as First LUNGevity Hero WASHINGTON, March 4, 2014 /PRNewswire-USNewswire/ -- The LUNGevity Foundation announces the LUNGevity Heroes program, a monthly honor recognizing individuals or organizations whose advocacy or research is making a difference in the fight against lung cancer. The top cancer killer in the United States, lung cancer, can affect anyone, regardless of smoking history, gender, or ethnicity, but remains underfunded and overlooked. LUNGevity Heroes...

2014-03-03 16:25:26

$250,000 to support immuno-oncology learning resources WASHINGTON, March 3, 2014 /PRNewswire-USNewswire/ -- LUNGevity Foundation is honored to announce a grant of $250,000 from Bristol-Myers Squibb for the development of educational materials on immuno-oncology. Progress in understanding lung cancer and treatment approaches has accelerated dramatically in the past several years after many slow decades. While no immunotherapeutic drugs are currently approved for lung cancer, this new area of...

2014-02-28 23:29:50

Medical Illustrations Improve and Enhance Health Literacy Throughout the World Atlanta, GA (PRWEB) February 28, 2014 Nucleus Medical Media, in an effort to support, improve, and enhance health literacy, has partnered with Dr. Tina St. John, author of “With Every Breath: A Lung Cancer Guidebook” to provide explanatory visuals to lung cancer patients and their families. Dr. St. John, whose husband passed away from lung cancer at a young age, created the Lung Cancer Guidebook to help...

2014-02-27 16:27:45

LCRF Grant Application Deadline June 16, 2014. NEW YORK, Feb. 27, 2014 /PRNewswire-USNewswire/ -- The Lung Cancer Research Foundation announced that it is accepting submissions of grant requests for medical/scientific research projects covering all aspects of lung cancer research. Submissions from investigators at all levels are encouraged including post-doctoral students to world leaders in the field. The maximum grant amount is $50,000 and the deadline for submission is June 16....

2014-02-25 14:34:50

Results Support Need for Combined Testing The findings of a recent study indicate that routine testing with both fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) may enhance the detection of ALK-positive non-small cell lung cancer (NSCLC). Accurate determination of ALK-positive tumors is necessary to identify patients with advanced NSCLC who are most likely to benefit from targeted therapy with an ALK inhibitor. The discovery of ALK rearrangement in about 1% to 7%...

2014-02-21 23:03:28

BerriHealth continues to support research for the neuroendocrine tumor and carcinoid cancer community. Portland, Oregon (PRWEB) February 21, 2014 BerriHealth, a leader in providing high-quality black raspberry powder for clinical trials and directly to consumers online, has donated a portion of their 2013 sales to New Orleans Louisiana Neuroendocrine Tumor Specialists (NOLANETS), led by Dr. Eugene Woltering. The program is a collaborative effort between the Louisiana State University...

2014-02-19 08:31:13

-- Ramucirumab Improved Survival in Second-Line Study of Patients with Non-Small Cell Lung Cancer -- INDIANAPOLIS, Feb. 19, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the REVEL trial, a global Phase III study of ramucirumab in combination with chemotherapy in patients with second-line non-small cell lung cancer (NSCLC), showed a statistically significant improvement in the primary endpoint of overall survival in the ramucirumab-plus-docetaxel arm...

2014-02-18 23:30:30

Company Will Present its Targeted and Personalized Medicine Approach to Lung Cancer Somerville, MA (PRWEB) February 18, 2014 Andarix Pharmaceuticals, a clinical stage company, announces that it has been selected to present its targeted lung cancer therapy at the 14th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting, also known as the Santa Monica Lung Cancer Meeting. This annual invitation-only meeting gathers the top scientists and clinicians to discuss the latest...


Latest lung cancer Reference Libraries

Clinical Lung Cancer
2012-05-14 11:09:55

Clinical Lung Cancer is a peer-reviewed medical journal published bimonthly by the CIG Media Group. It was established in 1999. As of May 2012, the editor-in-chief is David R. Gandara. Gandara is a member of the Board of Directors of the International Association for the Study of Lung Cancer and the Addario Foundation. He has also served as a member of the Board of Directors of the American Society of Clinical Oncology (ASCO) and as secretary-treasurer. He is furthermore a member of...

More Articles (1 articles) »
Word of the Day
pungle
  • To take pains; labor assiduously with little progress.
This word comes from the Spanish 'pongale,' put it.
Related